CALIXAR team will attend the BioPharm America virtual event from October 4 -5, 2022 to have exchanges on commercial and scientific opportunities related to our activities.CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently expanding its pipeline of highly druggable membrane protein targets and native antigens. In the coming years, CALIXAR will be able to offer pharmaceutical companies validated and discovery-ready native and functional therapeutic targets.CALIXAR aims at becoming a leader in the complex therapeutic targets-based (membrane proteins) drug development at the early discovery stage. Indeed, it is a thriving market expected to be worth 70 billion euros by 2025.About BioPharm America:BioPharm America™ Digital promotes an international audience of investors and industry leaders from major pharmaceutical companies, biotechnology companies of every size and stage, investors, and academic institutions which creates a robust exchange. It brings dealmakers from the life science ecosystem together to engage and reduce the enormous task of drug development.For more information and meet us: BioPharm America
